The financing was co-led by Forbion and Corteva to accelerate the commercial rollout of disease-resistant banana varieties.
"This funding is a powerful endorsement of our team’s ability to bring breakthrough products to the hands of growers, exporters and consumers around the world. We are entering a new era, one where gene‑edited crops will significantly enhance food security and sustainability. 2025 proved that our technology delivers – not in the distant future, but right now. With two banana varieties already on the market and demand outstripping supply, this investment enables us to scale global production and expand into new crops faster than ever before. We are excited to be partnering with our new investors as we progress our mission to build a world-leading tropical seeds company."
Union Square Ventures led the round to support the opening of 25 new manufacturing facilities and international expansion.
"Manufacturing is the origin of our security, prosperity and sense of purpose as nations. This Series A enables us to open more factories, invest in MasonOS, support exceptional franchisees and recruit the best engineers across Europe and the United States. Our mission is to forge industrial acceleration."
The Cambridge startup secured backing from National Grid Partners and Gresham House Ventures to scale its distributed quantum computing architecture.
"When we launched seven years ago, very few were thinking about networked or distributed quantum computing as a strategy for scaling, but we saw it as one of the most urgent and challenging outstanding problems in the industry, and set out to solve it. We’ve made great strides in shaping the market and the technology since then."
The financing round was led by IQ Capital to accelerate clinical trials for glioblastoma and other solid tumours.
"This significant investment accelerates our lead programme in glioblastoma and follow-on programme in colorectal cancer liver metastases through the clinic, advances our pipeline in liver and lung cancers, and further enhances our Odysseus platform. We are honoured to have the support of existing and new investors who share our mission to deliver breakthrough treatments and pursue cures for the thousands of patients and families facing devastating diagnoses each year."
